GlassScriptPhysician profile
Steve P Checroun
NPI 1801952387
$5,605.79
in general payments reported to CMS, 2019-2025
22 companies · $1,563 in 2025
The $1,563 reported for 2025 was more than what 85% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $760 · 2020: $726 · 2021: $410 · 2022: $840 · 2023: $314 · 2024: $993 · 2025: $1,563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,852 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,852.30 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,340.18 | 2022-2025 | Miebo, Infuse, Xiidra |
| Alcon Vision LLC | $1,156.25 | 2019-2025 | Tryptyr, Precision 1, Unity |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $611.58 | 2019-2021 | |
| Glaukos Corporation | $360.29 | 2024-2025 | Idosetr, Idose |
| Sun Pharmaceutical Industries INC. | $262.26 | 2022-2024 | |
| Johnson & Johnson Vision Care, INC. | $223.37 | 2019-2025 | Acuvue |
| Novartis Pharmaceuticals Corporation | $209.92 | 2019-2020 | |
| Allergan, INC. | $205.24 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $171.98 | 2025 | Xdemvy |
| Ocular Therapeutix, INC. | $150.00 | 2024 | |
| Rxsight INC | $115.85 | 2024 | Light Adjustable Lens (Lal), Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Mallinckrodt Hospital Products INC. | $109.60 | 2021 | |
| Ivantis, INC | $108.68 | 2019 | |
| Lkc Technologies, INC. | $105.40 | 2025 | |
| Aerie Pharmaceuticals, INC. | $102.03 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $95.30 | 2025 | Oxervate |
| Genentech USA, INC. | $81.04 | 2022 | |
| Apellis Pharmaceuticals, INC. | $80.28 | 2025 | Syfovre |
| Abbvie INC. | $53.50 | 2022-2025 | |
| Tearlab Corp | $22.80 | 2019 | |
| Thea Pharma INC. | $20.84 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Checroun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.